Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127272131 | 12727213 | 1 | I | 20160803 | 20160905 | 20160909 | 20160909 | EXP | FR-009507513-1609FRA003400 | MERCK | 60.44 | YR | M | Y | 0.00000 | 20160909 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127272131 | 12727213 | 1 | PS | AERIUS | DESLORATADINE | 1 | Oral | 10MG (REPORTED AS ^2 DF^), QD | 90 | MG | 21165 | 10 | MG | TABLET | QD | ||||
| 127272131 | 12727213 | 2 | SS | SANDIMMUN | CYCLOSPORINE | 1 | Intravenous (not otherwise specified) | STRENGTH 50MG/ML, 220 MG, QD | 660 | MG | 0 | 220 | MG | SOLUTION FOR INJECTION/INFUSION | QD | ||||
| 127272131 | 12727213 | 3 | SS | NEORAL | CYCLOSPORINE | 1 | Oral | 400 MG, QD | 0 | 400 | MG | CAPSULE | QD | ||||||
| 127272131 | 12727213 | 4 | SS | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 500MG (REPORTED AS ^1 DF^), QD | 4000 | MG | 0 | 500 | MG | TABLET | QD | ||||
| 127272131 | 12727213 | 5 | SS | THYMOGLOBULIN | LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 127272131 | 12727213 | 6 | SS | SIMVASTATIN ARROW | SIMVASTATIN | 1 | Oral | 40 MG (REPORTED AS 1 DF), QD | 0 | 40 | MG | FILM-COATED TABLET | QD | ||||||
| 127272131 | 12727213 | 7 | SS | ZYLORIC | ALLOPURINOL | 1 | Oral | 100MG (REPORTED AS ^1 DF^), QD | 0 | 100 | MG | TABLET | QD | ||||||
| 127272131 | 12727213 | 8 | SS | TIORFAN | RACECADOTRIL | 1 | Oral | 300MG (REPORTED AS ^3 DF^), QD | 900 | MG | 0 | 300 | MG | CAPSULE | QD | ||||
| 127272131 | 12727213 | 9 | SS | SMECTITE | MONTMORILLONITE | 1 | Oral | 3 DF, QD | 9 | DF | 0 | 3 | DF | QD | |||||
| 127272131 | 12727213 | 10 | SS | BISOPROLOL FUMARATE. | BISOPROLOL FUMARATE | 1 | Oral | 1 DF, QD | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127272131 | 12727213 | 6 | Hypercholesterolaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127272131 | 12727213 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127272131 | 12727213 | Acute kidney injury | |
| 127272131 | 12727213 | Confusional state | |
| 127272131 | 12727213 | Renal tubular necrosis | |
| 127272131 | 12727213 | Rhabdomyolysis | |
| 127272131 | 12727213 | Shock |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127272131 | 12727213 | 1 | 20160726 | 20160803 | 0 | |
| 127272131 | 12727213 | 2 | 20160801 | 20160810 | 0 | |
| 127272131 | 12727213 | 3 | 20160812 | 20160818 | 0 | |
| 127272131 | 12727213 | 4 | 20160727 | 20160822 | 0 | |
| 127272131 | 12727213 | 5 | 20160730 | 20160731 | 0 | |
| 127272131 | 12727213 | 6 | 20160821 | 0 | ||
| 127272131 | 12727213 | 7 | 20160818 | 0 | ||
| 127272131 | 12727213 | 8 | 20160801 | 20160803 | 0 | |
| 127272131 | 12727213 | 9 | 20160801 | 20160803 | 0 | |
| 127272131 | 12727213 | 10 | 20160822 | 0 |